Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
AMICUS THERAPEUTICS, INC. incurred term loan of $400 million with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. at 3-month Term SOFR, subject to a 2.5% floor, plus a Term SOFR adjustment of 0.261 maturing six years from the date of the funding of the Term Loan.
- Instrument
- term loan
- Principal
- $400 million
- Counterparty
- Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.
- Rate
- 3-month Term SOFR, subject to a 2.5% floor, plus a Term SOFR adjustment of 0.261
- Maturity
- six years from the date of the funding of the Term Loan
- Event
- incurrence
Exact text from the filing
respective meanings ascribed to such terms in the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K. The Loan Agreement provides for a $400 million senior secured Term Loan to be extended to Amicus, on or about October 5, 2023, subject to entry into a security agreement and delivery of other customary deliverables. The
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AMICUS THERAPEUTICS, INC. entered into Purchase Agreement with purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone valued at aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share (effective 2023-10-02).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone
- Value
- aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, Amicus entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone, for the private placement (the “Private Placement”) of an aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share (the “Common Stock”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AMICUS THERAPEUTICS, INC. entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. valued at $400 million senior secured Term Loan (effective 2023-10-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.
- Value
- $400 million senior secured Term Loan
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, Amicus Therapeutics, Inc., a Delaware corporation (“Amicus” or the “Company”) entered into a Loan Agreement (the “Loan Agreement”), by and among Amicus, as the borrower (the “Borrower”), certain subsidiaries of Amicus from time to time party thereto as guarantors (the “Guarantors”), Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”) and Wilmington Trust, National Association, as Agent (the “Agent”) for certain lenders from time to time party thereto (collectively, the “Lenders”).
View on SEC.gov